All Publications

The Cancer Drugs Fund in practice and under the new framework

Indirect comparison of ACR response of biologic treatments in active SJIA

Tocilizumab in polyarticular juvenile idiopathic arthritis: a cost-utility model for the United Kingdom

Cost-utility of tocilizumab in the treatment of systemic juvenile idiopathic arthritis in Finland

Clinical effectiveness analysis of bosentan, epoprostenol, iloprost, sildenafil and treprostinil in treatment of pulmonary arterial hypertension

Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation

Cost-effectiveness analysis of alternative antiviral strategies for the treatment of HBeAg-positive and HBeAg-negative chronic hepatitis B in the United Kingdom

The cost-effectiveness of supervised exercise for the treatment of intermittent claudication

Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation

Tocilizumab in methotrexate-naïve rheumatoid arthritis: a cost-utility model for Slovakia

Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK

Economic evaluation of tocilizumab combination in the treatment of moderate to severe rheumatoid arthritis in Italy

An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement

Cost–effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden

Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer’s perspective

Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer’s perspective

Topical therapies for the treatment of localized plaque psoriasis in primary care: a cost-effectiveness analysis

Topical therapies for the treatment of plaque psoriasis: systematic review and network meta-analyses

Biological therapies for the treatment of severe psoriasis in patients with previous exposure to biological therapy: a cost-effectiveness analysis

Systematic review of the impact of urinary tract infections on health-related quality of life

Intermittent self catheterisation with hydrophilic, gel reservoir, and non-coated catheters: a systematic review and cost effectiveness analysis

A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK

The ethics of paediatric anti-depressant use: erring on the side of caution

Cost-effectiveness of asenapine in the treatment of bipolar I disorder patients with mixed episodes

Research methods to change clinical practice for patients with rare cancers

Providing public health information to prevent skin cancer: review of effectiveness and cost-effectiveness

An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom

An indirect treatment comparison of cabozantinib verse vandetanib in progressive medullary thyroid cancer (MTC)

Problems of variable biomarker evaluation in stratified medicine research: a case study of ERCC1 in non-small-cell lung cancer

Societal costs of Er+/Her2- advanced or metastatic breast cancer in post-menopausal women in the United Kingdom

Long‐term efficacy of novel therapies in moderate‐to‐severe plaque psoriasis: a systematic review and network meta‐analysis of PASI response

The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis

Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective

Economic evaluation of insertable cardiac monitors in detecting previously undiagnosed atrial fibrillation and subsequently moderating stoke risk in a high-risk population in the United Kingdom

Economic evaluation of insertable cardiac monitors to detect atrial fibrillation and subsequently moderate stroke risk in a high-risk population in the UK

Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke

Pharmacoeconomic assessment of nintedanib for the treatment of idiopathic pulmonary fibrosis in the Greek healthcare system

Cost-Effectiveness of nintedanib in idiopathic pulmonary fibrosis in the U.S.

Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada

The cost of somatisation among the working‐age population in England for the year 2008–2009

Influence of idiopathic pulmonary fibrosis progression on healthcare resource use

A cost-effectiveness analysis of nintedanib in idiopathic pulmonary fibrosis in the UK

The burden of illness of idiopathic pulmonary fibrosis: a comprehensive evidence review

The burden of illness of idiopathic pulmonary fibrosis: a comprehensive evidence review

UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug

Efficacy Of Novel Dmards In Early Active Rheumatoid Arthritis: An Indirect Comparison

Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain